- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT03215147
Prevalence and Impact on Quality of Life of Airway Disease in Patients With Idiopathic Pulmonary Fibrosis
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
Idiopathic pulmonary fibrosis (IPF) is defined as a specific form of chronic, progressive fibrosing interstitial pneumonia of unknown cause, occurring primarily in older adults, and limited to the lungs. It is characterized by progressive worsening of dyspnea and lung function and is associated with a poor prognosis.
The main symptoms of patients with IPF are dyspnea on exertion and a persistent dry cough or mildly productive cough.
In many IPF patients, cough is often the first symptom, preceding dyspnea on exertion sometimes by years. It affects upwards of 70-85% of patients with IPF.
Chronic obstructive pulmonary disease (prevalence rate 4-18%) and asthma (prevalence rate 5.9-9.9%) are the airway disease whose main symptoms are also dyspnea and cough.
To date, the effect of airway disease has not been well studied in patients with idiopathic pulmonary fibrosis, and the prevalence is unknown in Korea.
Unlike idiopathic pulmonary fibrosis, airway disease is a treatable, modifiable disease, so treatment of these diseases may improve QOL in IPF patients.
Therefore, this study's purpose is A. Identify the prevalence of airway disease in IPF patients B. Identify differences in QOL and symptoms according to presence of airway disease C. Identify the symptomatic improvement after active treatment for the airway diseases
Type d'étude
Inscription (Anticipé)
Contacts et emplacements
Coordonnées de l'étude
- Nom: Choi Sun Mi
- Numéro de téléphone: 02-2072-4915
- E-mail: sunmich81@gmail.com
Sauvegarde des contacts de l'étude
- Nom: PARK HEEMOON
- E-mail: coramdeo33@gmail.com
Lieux d'étude
-
-
-
Seoul, Corée, République de
- Recrutement
- Seoul National University Hospital
-
Contact:
- Choi Sun Mi
- Numéro de téléphone: 02-2072-4915
- E-mail: sunmich81@gmail.com
-
Contact:
- PARK HEEMOON
- E-mail: coramdeo33@gmail.com
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
- Enfant
- Adulte
- Adulte plus âgé
Accepte les volontaires sains
Sexes éligibles pour l'étude
Méthode d'échantillonnage
Population étudiée
La description
Inclusion Criteria:
- IPF patients
Exclusion Criteria:
- Patients on systemic steroid
- Patients with acute exacerbation within the last 6 months
- PFT+BDR, MBPT contra-indication
- SpO2 < 90%
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
---|---|---|
Number of participants who have asthma combined with idiopathic pulmonary fibrosis
Délai: Through study completion, an average of 2 year
|
Confirmation of asthma : pulmonary function test with bronchodilator response or Methacholine provocation test
|
Through study completion, an average of 2 year
|
Number of participants who have COPD combined with idiopathic pulmonary fibrosis
Délai: Through study completion, an average of 2 year
|
Confirmation of COPD : pulmonary function test with bronchodilator response
|
Through study completion, an average of 2 year
|
Number of participants who have Eosinophilic bronchitis combined with idiopathic pulmonary fibrosis
Délai: Through study completion, an average of 2 year
|
Confirmation of Eosinophilic bronchitis : pulmonary function test with bronchodilator response, induced sputum
|
Through study completion, an average of 2 year
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
---|---|---|
The difference of CAT scores between patients with airway disease and those without airway disease.
Délai: baseline and after treating the airway disease for 6~8 weeks
|
Quality of life : COPD assessment test(CAT)
|
baseline and after treating the airway disease for 6~8 weeks
|
The difference of SGRQ scores to assess quality of life between patients with airway disease and those without airway disease.
Délai: baseline and after treating the airway disease for 6~8 weeks
|
Quality of life : St George's Respiratory Questionnaire(SGRQ)
|
baseline and after treating the airway disease for 6~8 weeks
|
The difference of mMRC scores to assess symptom severity between patients with airway disease and those without airway disease.
Délai: baseline and after treating the airway disease for 6~8 weeks
|
Symptom severity : mMRC
|
baseline and after treating the airway disease for 6~8 weeks
|
The difference of distance of 6MWT to assess symptom severity between patients with airway disease and those without airway disease.
Délai: baseline and after treating the airway disease for 6~8 weeks
|
Symptom severity : 6 minute walking test(6MWT)
|
baseline and after treating the airway disease for 6~8 weeks
|
The difference of EQ-5D-VAS scores to assess symptom severity between patients with airway disease and those without airway disease.
Délai: baseline and after treating the airway disease for 6~8 weeks
|
Symptom severity : EQ-5D-VAS
|
baseline and after treating the airway disease for 6~8 weeks
|
The difference of CQLQ scores to assess symptom severity between patients with airway disease and those without airway disease.
Délai: baseline and after treating the airway disease for 6~8 weeks
|
Symptom severity : Cough Quality-of-Life Questionnaire(CQLQ)
|
baseline and after treating the airway disease for 6~8 weeks
|
Checking the improvement of CAT score to assess the quality of life between patients with airway disease and those without airway disease
Délai: After treating the airway disease for 6~8 weeks
|
Quality of life : COPD assessment test(CAT)
|
After treating the airway disease for 6~8 weeks
|
Checking the improvement of SGRQ score to assess the quality of life between patients with airway disease and those without airway disease
Délai: After treating the airway disease for 6~8 weeks
|
Quality of life : St George's Respiratory Questionnaire(SGRQ)
|
After treating the airway disease for 6~8 weeks
|
Checking the improvement of mMRC scores to assess symptom severity between patients with airway disease and those without airway disease
Délai: After treating the airway disease for 6~8 weeks
|
Symptom severity : mMRC
|
After treating the airway disease for 6~8 weeks
|
Checking the improvement of distance of 6MWT to assess symptom severity between patients with airway disease and those without airway disease
Délai: After treating the airway disease for 6~8 weeks
|
Symptom severity : 6 minute walking test(6MWT)
|
After treating the airway disease for 6~8 weeks
|
Checking the improvement of EQ-5D-VAS score to assess symptom severity between patients with airway disease and those without airway disease
Délai: After treating the airway disease for 6~8 weeks
|
Symptom severity : EQ-5D-VAS
|
After treating the airway disease for 6~8 weeks
|
Checking the improvement of CQLQ to assess symptom severity between patients with airway disease and those without airway disease
Délai: After treating the airway disease for 6~8 weeks
|
Symptom severity : Cough Quality-of-Life Questionnaire(CQLQ)
|
After treating the airway disease for 6~8 weeks
|
Collaborateurs et enquêteurs
Parrainer
Les enquêteurs
- Chercheur principal: Choi Sun Mi, Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine and Lung institute, Seoul National University College of Medicine, Seoul, Korea
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Anticipé)
Achèvement de l'étude (Anticipé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- ILD Asthma
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .